Leading life sciences clients turn to DLA Piper for its capabilities in financing matters, including equity arrangements and strategic stake acquisitions. The firm is also well placed to advise on corporate transactions, regulatory, product liability, and data protection matters. The team is led by Birmingham-based Richard Taylor, a commercial and IP law specialist. Simon Persoff joined the practice from Clifford Chance LLP in September 2024, bringing experience in data privacy.
Legal 500 Editorial commentary
Testimonials
Collated independently by Legal 500 research team.
- 'Very responsive, supportive and easy to work with.'
Key clients
- Pfizer
- Medtronic
- Sanofi
- Eli Lilly
- AbbVie
- Bristol Myers Squibb
- Novartis
- Takeda
- ResMed
- GlaxoSmithKline
- Vertex
- Dexcom
- Incyte
- Ipsen
- WuXi Apptec
- Medica Group
- Syneos Health
Work highlights
Advised a consortium of investors led by Pfizer Ventures on a £40.5 million Series A2 preferred share financing in UK-based Curve Therapeutics, a biotechnology company developing novel cancer drugs.
Advised MidEuropa on the acquisition of a controlling stake in FAMAR, the pharmaceutical contract development and manufacturing organisation (CDMO), from ECM Partners and Metric Capital Partners.
Advised ASX-listed Starpharma on its strategic partnership with Medicxi, a life sciences investment firm dedicated to financing companies developing innovative medicines, to co-found a new UK-based company called Petalion Therapeutics.
Practice head
Richard Taylor
Other key lawyers
Simon Persoff